Cancer prevention and vitamin K antagonists: an overview (Q37740293)

22 August 2017

1 reference

title

Cancer prevention and vitamin K antagonists: an overview (English)

1 reference

22 August 2017

0 references

0 references

1 reference

Gentian Denas

2

0 references

Vittorio Pengo

series ordinal

1

object named as

Vittorio Pengo

1 reference

22 August 2017

author name string

Seena Padayattil Jose

series ordinal

3

1 reference

22 August 2017

Martino F Pengo

series ordinal

4

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

125 Suppl 2

1 reference

22 August 2017

page(s)

S103-5

1 reference

Inhibition of metastases by anticoagulants

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Antitumor and antimetastatic effect of warfarin and heparins.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Hemostasis and malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Tissue factor in hemostasis and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

The role of the coagulation system in tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Anticoagulants in thrombosis and cancer: the missing link

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Tissue factor, thrombin, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Warfarin Treatment of Mice Bearing Autochthonous Tumors: Effect on Spontaneous Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

The first international urokinase/warfarin trial in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Does warfarin therapy influence the risk of bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Clinical studies with anticoagulants to improve survival in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

Does antithrombotic therapy improve survival in cancer patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970025-6

7 January 2021

10.1016/S0049-3848(10)70025-6

Identifiers

DOI

1 reference

22 August 2017

1 reference